NORCROSS, Ga., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced that Peter G. Traber, M.D., the Company's chief executive officer and chief medical officer, has been named the Chair of the Anti-Fibrotic Drug Development Summit 2017. The Summit, which is dedicated to the translation of fibrotic mechanisms into clinically effective therapeutics, will take place November 13-14 at the Hyatt Regency Boston, Boston, MA.
As Chair, Dr. Traber will deliver opening and closing remarks on both days of the Summit. Increasingly recognized as one of the leading authorities on the diagnosis and treatment of fibrotic disease, Dr. Traber also recently served as chair of the NASH Summit Europe.
Dr. Traber, said, "I consider this not only a great honor, but further appreciation for the hard work of the entire Galectin therapeutics team and our efforts to combat fibrosis. By Chairing and participating in AFDD, we can advance the growing body of knowledge that is tying an increasingly wide array of disorders to fibrosis."
The AFDD Summit brings together drug developers focused on organ-specific indications to participate in a cross disciplinary, multi-organ discussion in order to gain new insights into their anti-fibrotic drug development research. AFDD is an opportunity to hear from, and interact with, thought-leaders from firms such as AbbVie, Biogen, Genentech, Pfizer and others to help accelerate anti-fibrotic drug candidate development.
Galectin Therapeutics anticipates announcing top-line results from its NASH-CX trial in December 2017. Further information on the NASH-CX trial is also available at www.clinicaltrials.gov
About Galectin Therapeutics
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Galectin's lead drug (GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein that is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH related fibrosis. This is the most common liver disease and one of the largest drug development opportunities available today. Additional development programs are for treatment of severe atopic dermatitis, moderate-to-severe plaque psoriasis, and in combination immunotherapy for advanced melanoma and other malignancies. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com.
Contacts:
Galectin Therapeutics, Inc.
Jack Callicutt, Chief Financial Officer
678-620-3186
ir@galectintherapeutics.com